Novartis
The latest news about Novartis: headlines, AI summaries and the full story from every source.
- Morgan Stanley Highlights Amgen's Competitive Position After Novartis Heart Drug Trial Failure
- Amgen Stock Drops Sharply Amid Novartis' Lp(a)-Lowering Drug Failure
- Investors Scrutinize Novartis' M&A Strategy After Drug Trial Setbacks
- Royalty Pharma's Pelacarsen Fails Phase 3 Trial; Focus Shifts to Spinraza Royalties
- Novartis Stock Drops After Key Drug Trial Failures
- Dow Jones Falls Sharply Due to Novartis' Failed Drug Trials
- Novartis Faces Key Risks Despite Promising New Multiple Sclerosis Drug
- Stocks Slide Amid Rising Oil Prices and Geopolitical Tensions
- Novartis' Upcoming Clinical Trial Results Could Shape Long-Term Growth Outlook
- Novartis Q1 EPS and Revenue Miss Estimates, Maintains 2026 Growth Outlook
- Novartis CEO Warns of Long-Term Implications of Trump's Drug Pricing Policy
- Novartis Reports Missed Q1 Estimates, Reaffirms Full-Year 2026 Guidance